News & Articles
- The Deal: Spectrum Expands Cancer Line With Talon Buy
NEW YORK (The Deal) -- Las Vegas-based Spectrum Pharmaceuticals Inc. is amping up its cancer therapy offerings with the acquisition of private equity-backed Talon Therapeutics Inc., paying $11.3 million up-front plus contingent value rights, or CVRs, of $195 million. The CVRs are based on goals set for Talon's two lead drug candidates, lymphoma drug Marqibo and Menadione Topical Lotion. Marqibo ...
July 18, 2013 - TheStreet.com